What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Poultry Mycoplasma Infections: Vaccination Strategies and Control

Etiology and Classification

Avian mycoplasmosis is primarily caused by several pathogenic species within the genus Mycoplasma, the most significant being Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS). Other pathogenic species include Mycoplasma meleagridis (MM) and Mycoplasma iowae (MI), which predominantly affect turkeys. Mycoplasmas are the smallest self-replicating prokaryotes, lacking a cell wall, which renders them intrinsically resistant to beta-lactam antimicrobials and confers a pleomorphic morphology. Their small genome (approximately 800-1000 kbp) limits biosynthetic capacity, necessitating a parasitic lifestyle reliant on host-derived nutrients such as cholesterol and nucleic acid precursors. The absence of a cell wall also makes them susceptible to osmotic lysis and desiccation, influencing their survival outside the host.

Epidemiology and Transmission

Transmission of pathogenic mycoplasmas in poultry occurs both vertically (transovarian) and horizontally (direct contact, aerosol, fomites). Vertical transmission is a critical feature of MG, MS, MM, and MI epidemiology, as infected breeder flocks can introduce infection into progeny at hatch. Horizontal transmission occurs through respiratory droplets, contaminated feed, water, and equipment. The incubation period for MG is typically 10-21 days, while MS may exhibit a slightly longer range. Once introduced into a flock, infection can become endemic, with carrier birds serving as persistent reservoirs. Concurrent infections with respiratory viruses (e.g., Newcastle disease virus, infectious bronchitis virus) or bacteria (e.g., Escherichia coli, Ornithobacterium rhinotracheale) can exacerbate clinical disease severity.

Clinical Signs and Pathogenesis

Mycoplasma gallisepticum (Chronic Respiratory Disease)

MG is the primary etiologic agent of chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys. Clinical signs include rales, coughing, sneezing, nasal discharge, and conjunctivitis. In turkeys, infraorbital sinus swelling is a characteristic finding. Morbidity is high, but mortality is typically low unless complicated by secondary pathogens. In layers, MG infection leads to a significant drop in egg production (10-30%) and an increase in eggshell abnormalities. The pathogenesis involves adherence of MG to ciliated respiratory epithelial cells via specialized adhesins (e.g., GapA, CrmA), leading to ciliostasis, epithelial cell damage, and an influx of inflammatory cells. The resulting exudate and airway obstruction contribute to the characteristic respiratory signs.

Mycoplasma synoviae (Infectious Synovitis and Respiratory Infection)

MS causes two distinct clinical presentations: infectious synovitis and subclinical respiratory infection. Infectious synovitis is characterized by lameness, swollen joints (hock and wing joints), and breast blisters. Affected birds exhibit reluctance to move, reduced feed intake, and stunted growth. The respiratory form is often subclinical but can manifest as mild rales and airsacculitis, particularly in broilers. MS is also a recognized cause of eggshell apex abnormalities (EAA) in layer flocks, resulting in a characteristic roughened, thickened, and discolored region at the narrow end of the egg. The pathogenesis of synovitis involves hematogenous dissemination of MS from the respiratory tract to the synovial membranes, where it induces a fibrinous, purulent inflammation.

Mycoplasma meleagridis and Mycoplasma iowae

MM is a significant pathogen in turkeys, causing airsacculitis, skeletal abnormalities (e.g., leg deformities), and reduced hatchability. MI is associated with embryo mortality, reduced hatchability, and leg problems in turkey poults. Both species are efficiently transmitted vertically.

Diagnosis

Accurate diagnosis is essential for effective control. Laboratory methods include serology, culture, and molecular detection.

Serology

Serological testing is widely used for flock screening. The rapid serum agglutination (RSA) test is a simple, inexpensive screening tool but can yield false positives due to cross-reactions with other mycoplasma species or non-specific agglutinins. The hemagglutination inhibition (HI) test is more specific and is often used to confirm RSA-positive samples. Commercial enzyme-linked immunosorbent assay (ELISA) kits are available for both MG and MS and offer high throughput and quantitative results. Serology is valuable for monitoring flock status but cannot distinguish between vaccinated and naturally infected birds unless DIVA (Differentiating Infected from Vaccinated Animals) strategies are employed.

Culture

Mycoplasma culture is the gold standard for definitive diagnosis but is technically demanding and time-consuming (requiring 7-21 days). Samples (tracheal swabs, air sac exudate, synovial fluid) are inoculated into specialized liquid and solid media (e.g., Frey's medium, modified Hayflick's medium) supplemented with serum and yeast extract. Colonies exhibit a characteristic "fried egg" appearance on solid media. Species identification is confirmed by immunofluorescence or molecular methods.

Molecular Detection

Polymerase chain reaction (PCR) assays, including real-time PCR (qPCR), are now the preferred diagnostic tools due to their high sensitivity, specificity, and rapid turnaround time. PCR can detect mycoplasma DNA directly from clinical samples, including tracheal swabs, choanal cleft swabs, and tissue homogenates. Species-specific PCR assays targeting the 16S rRNA gene, mgc2 gene (for MG), or vlhA gene (for MS) are commonly used. Molecular typing methods, such as gene-targeted sequencing (e.g., mgc2, vlhA), allow for epidemiological tracking of strain variants.

Vaccination Strategies

Vaccination is a cornerstone of poultry mycoplasma vaccine programs, particularly in multi-age commercial layer and breeder operations where eradication is impractical. Two main types of vaccines are available: live attenuated vaccines and inactivated (killed) bacterins.

Live Attenuated Vaccines

Live vaccines are derived from naturally occurring or chemically induced attenuated strains of MG or MS. The most widely used live MG vaccine strains include the F strain, ts-11, and 6/85. The F strain is moderately virulent and can displace wild-type MG in multi-age flocks but retains some pathogenicity, particularly in turkeys. The ts-11 strain is a temperature-sensitive mutant that replicates at the lower temperature of the upper respiratory tract (33-34 degrees Celsius) but not at core body temperature (41 degrees Celsius), providing a high safety margin. The 6/85 strain is a non-pathogenic, non-transmissible strain that is administered via spray or drinking water.

Live MS vaccines, such as the MS-H strain (a temperature-sensitive mutant), are used to protect against infectious synovitis and respiratory disease. Live vaccines are typically administered to pullets before the onset of lay via eye drop, spray, or drinking water. They induce a local mucosal immune response (IgA) and systemic humoral immunity (IgG). The primary advantage of live vaccines is their ability to stimulate strong, long-lasting immunity and, in some cases, to displace field strains. Disadvantages include the potential for reversion to virulence (though rare for ts-11 and 6/85), vaccine-induced seroconversion that complicates serological monitoring, and the risk of vaccine strain transmission to unvaccinated flocks.

Inactivated (Killed) Vaccines

Inactivated vaccines are prepared from whole-cell mycoplasma cultures that are chemically inactivated (e.g., with formalin or beta-propiolactone) and emulsified with an adjuvant (e.g., oil-in-water or water-in-oil). They are administered via intramuscular or subcutaneous injection, typically to pullets 8-16 weeks of age. Inactivated vaccines induce a strong systemic humoral immune response (IgG) but are less effective at stimulating local mucosal immunity compared to live vaccines. They are safe, cannot revert to virulence, and do not spread horizontally. However, they require individual bird handling, are more labor-intensive to administer, and may not provide complete protection against respiratory challenge. Inactivated vaccines are often used in combination with live priming (prime-boost strategy) to enhance immunity.

Vaccine Efficacy and Limitations

The efficacy of poultry mycoplasma vaccine programs depends on multiple factors, including vaccine strain, route of administration, timing, flock health, and the level of field challenge. Vaccination reduces clinical signs, airsacculitis lesions, and egg production losses but does not always prevent infection or colonization. Vaccinated birds can still become infected with field strains and may shed the organism, albeit at lower levels. Therefore, vaccination is a component of an integrated control program, not a standalone solution.

DIVA Strategies

DIVA strategies are essential for serological monitoring in vaccinated flocks. For MG, the ts-11 and 6/85 strains lack certain immunodominant epitopes present in wild-type strains, allowing the use of specific ELISA tests that detect antibodies against these epitopes. For MS, the MS-H vaccine strain has a specific vlhA gene signature that can be differentiated from field strains by PCR and sequencing. These DIVA approaches enable producers to distinguish vaccine-induced seroconversion from natural infection.

Integrated Control Programs

Effective control of poultry mycoplasmosis requires a multi-faceted approach combining biosecurity, management, vaccination, and, where feasible, eradication.

Biosecurity

Strict biosecurity is the first line of defense. This includes:

Maintaining closed flocks or sourcing replacement stock from certified mycoplasma-free breeders.
Implementing all-in/all-out production systems to break the cycle of infection.
Strict visitor and equipment sanitation protocols.
Rodent and wild bird control, as these can serve as mechanical vectors.
Dedicated footwear and clothing for each house.

Eradication

Eradication of MG and MS from primary breeder flocks is a goal of many national poultry health programs. Eradication involves:

Regular serological and molecular surveillance of all breeder flocks.
Immediate culling of seropositive flocks.
Depopulation, cleaning, disinfection, and downtime before repopulation.
Strict biosecurity to prevent reintroduction.

Eradication is most feasible in single-age, high-health-status operations. It is less practical in multi-age, multi-site production systems.

Antimicrobial Therapy

Antimicrobial therapy can reduce clinical signs and shedding but does not eliminate infection. Drugs with activity against mycoplasmas include tetracyclines, tylosin, tilmicosin, tiamulin, enrofloxacin, and florfenicol. However, antimicrobial resistance is an increasing concern, and the use of antibiotics in poultry is subject to regulatory restrictions in many jurisdictions. Antimicrobial therapy is not a substitute for vaccination and biosecurity.

Monitoring and Surveillance

Ongoing monitoring is critical for early detection and control. This includes:

Routine serological testing (RSA, HI, ELISA) of sentinel birds or representative samples.
PCR testing of tracheal swabs from birds with respiratory signs or at key production stages (e.g., before moving to lay).
Postmortem examination and culture of suspect cases.

Decision Tree for Mycoplasma Control

The following Mermaid diagram illustrates a decision framework for implementing a mycoplasma control program in a commercial layer or breeder flock.

flowchart TD
    A[Flock Mycoplasma Status Unknown], > B{Serological Screening}
    B, >|Negative| C[Maintain Biosecurity]
    B, >|Positive| D{Confirm with PCR}
    D, >|Wild-type MG/MS Detected| E{Production Type}
    E, >|Breeder| F[Eradication Program]
    E, >|Commercial Layer| G[Vaccination Program]
    G, > H[Select Vaccine Type]
    H, > I[Live Attenuated]
    H, > J[Inactivated]
    I, > K[Administer via spray/drinking water]
    J, > L[Administer via injection]
    K, > M[Monitor with DIVA serology]
    L, > M
    M, > N[Assess Clinical Protection]
    N, >|Adequate| O[Continue Surveillance]
    N, >|Inadequate| P[Review Vaccine Strain/Protocol]
    P, > H
    F, > Q[Depopulate and Disinfect]
    Q, > R[Repopulate with Mycoplasma-Free Stock]
    R, > C
    D, >|Vaccine Strain Only| S[No Action Needed]
    S, > O

Conclusion

Poultry mycoplasma infections caused by MG and MS remain a significant economic burden on the global poultry industry. Effective control requires a comprehensive strategy that integrates rigorous biosecurity, accurate diagnostics, and strategic vaccination. Live attenuated and inactivated poultry mycoplasma vaccine options are available, each with distinct advantages and limitations. The choice of vaccine and vaccination protocol must be tailored to the specific production system, disease prevalence, and regulatory environment. Eradication remains the gold standard for primary breeders, while vaccination and management are essential for commercial layers and broilers. Continued research into improved vaccines, DIVA technologies, and antimicrobial alternatives is necessary to further enhance control of these persistent pathogens.

References

Ley, D. H. (2008). Mycoplasma gallisepticum infection. In Y. M. Saif, A. M. Fadly, J. R. Glisson, L. R. McDougald, L. K. Nolan, & D. E. Swayne (Eds.), Diseases of Poultry (12th ed., pp. 807-834). Blackwell Publishing.
Kleven, S. H. (2008). Mycoplasma synoviae infection. In Y. M. Saif, A. M. Fadly, J. R. Glisson, L. R. McDougald, L. K. Nolan, & D. E. Swayne (Eds.), Diseases of Poultry (12th ed., pp. 845-856). Blackwell Publishing.
Bradbury, J. M. (2005). Poultry mycoplasmas: sophisticated pathogens in simple guise. British Poultry Science, 46(2), 125-136.
Whithear, K. G. (1996). Control of avian mycoplasmoses by vaccination. Revue Scientifique et Technique (International Office of Epizootics), 15(4), 1527-1553.
Noormohammadi, A. H. (2007). Role of phenotypic diversity in pathogenesis of avian mycoplasmosis. Avian Pathology, 36(6), 439-444.
Ferguson-Noel, N. M., & Williams, S. M. (2015). The efficacy of Mycoplasma gallisepticum vaccines in commercial layers. Avian Diseases, 59(1), 1-6.
Feberwee, A., de Wit, J. J., & Landman, W. J. M. (2005). Induction of eggshell apex abnormalities by Mycoplasma synoviae: field and experimental studies. Avian Pathology, 34(3), 221-228.
Raviv, Z., & Ley, D. H. (2006). Mycoplasma gallisepticum vaccine strain ts-11: a review. Avian Diseases, 50(4), 481-487.
Morrow, C. J., & Whithear, K. G. (1996). Application of the ts-11 vaccine strain of Mycoplasma gallisepticum in commercial layer flocks. Australian Veterinary Journal, 74(6), 439-442.
Kleven, S. H. (1998). Mycoplasmas in the etiology of multifactorial respiratory disease. Poultry Science, 77(8), 1146-1149.
Stipkovits, L., & Kempf, I. (1996). Mycoplasmoses in poultry. Revue Scientifique et Technique (International Office of Epizootics), 15(4), 1495-1525.
Marois, C., Dufour-Gesbert, F., & Kempf, I. (2002). Polymerase chain reaction for detection of Mycoplasma gallisepticum in environmental samples. Avian Pathology, 31(2), 163-168.
Gole, V. C., Chousalkar, K. K., & Roberts, J. R. (2012). Prevalence of antibodies to Mycoplasma gallisepticum and Mycoplasma synoviae in Australian commercial layer flocks. Australian Veterinary Journal, 90(7), 263-267.
Landman, W. J. M., & Feberwee, A. (2004). Aerosol-induced Mycoplasma synoviae arthritis: the role of infectious dose and immune status. Avian Pathology, 33(4), 401-408.
Catania, S., Bilato, D., Gobbo, F., Granato, A., Terregino, C., & Iob, L. (2010). Isolation of Mycoplasma synoviae from wild birds. Avian Pathology, 39(4), 293-296.
Nascimento, E. R., & Yamamoto, R. (1986). The effect of Mycoplasma gallisepticum on the immune response of chickens. Avian Diseases, 30(3), 507-512.
Yoder, H. W. (1986). A historical account of the diagnosis and control of avian mycoplasmosis. Avian Diseases, 30(1), 1-7.
Jordan, F. T. W. (1985). Mycoplasma infections in poultry. In The Mycoplasmas (Vol. 4, pp. 1-48). Academic Press.
Bencina, D., & Bradbury, J. M. (1992). Combination of immunofluorescence and immunoperoxidase techniques for serotyping Mycoplasma gallisepticum and Mycoplasma synoviae. Avian Pathology, 21(2), 295-304.
Talkington, F. D., & Kleven, S. H. (1985). Evaluation of protection against Mycoplasma gallisepticum infection in chickens vaccinated with the F strain. Avian Diseases, 29(4), 1044-1053.

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.